Loteprednol and tobramycin in combination: A review of their impact on current treatment regimens

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 5, 2010, Pages 843-852

  Comstock, Timothy L ^a   Holland, Edward J ^b  

^a BAUSCH AND LOMB   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Corticosteroids; Intraocular pressure; LE T; Loteprednol etabonate; Ocular infection; Ocular inflammation; Tobramycin; Zylet

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; DEXAMETHASONE PLUS TOBRAMYCIN; FLUOROMETHOLONE; LOTEPREDNOL ETABONATE; LOTEPREDNOL ETABONATE PLUS TOBRAMYCIN; PLACEBO; PREDNISOLONE ACETATE; RIMEXOLONE; TOBRAMYCIN;

ABNORMAL SENSATION; ALLERGIC CONJUNCTIVITIS; AQUEOUS HUMOR; AQUEOUS HUMOR OUTFLOW; BACTERICIDAL ACTIVITY; BINDING AFFINITY; BLEPHARITIS; BLEPHAROKERATOCONJUNCTIVITIS; BURNING SENSATION; CATARACT; CLINICAL TRIAL; CONJUNCTIVITIS; CORNEA INJURY; DISEASE COURSE; DISEASE SEVERITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; DRY EYE; EYE BURNING; EYE INFECTION; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; FOREIGN BODY SENSATION; GIANT PAPILLARY CONJUNCTIVITIS; GLAUCOMA; HUMAN; INCIDENCE; INFECTION RESISTANCE; INFECTION RISK; INTRAOCULAR PRESSURE; KERATITIS; KERATOCONJUNCTIVITIS; NONHUMAN; OCULAR PRURITUS; OPTIMAL DRUG DOSE; PAIN; PATIENT COMPLIANCE; PHOTOSENSITIVITY; POSTOPERATIVE INFLAMMATION; PRURITUS; REVIEW; RISK ASSESSMENT; SEASONAL ALLERGIC CONJUNCTIVITIS; SIDE EFFECT; STINGING SENSATION; TREATMENT DURATION; UVEITIS; VISION; VISUAL ACUITY; WOUND HEALING IMPAIRMENT;

EID: 77949435985     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003667532     Document Type: Review

References (57)

1. Lim W-K, Fujimoto C, Ursea R, et al. Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol 2005;123:957-963
2. Rothova A, Suttorp-van Schulten M, Frits-Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Ophthalmol 1996;80:332-336
3. Cho H, Wolf K, Wolf E. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol 2009;3:199-210
4. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 2008;92:455-459
5. Bielory L. Update on ocular allergy treatment. Expert Opin Pharmacother 2002;3:541-553
6. Becker MD, Smith JR, Max R, Fiehn C. Management of sight-threatening uveitis: new therapeutic options. Drugs 2005;65:497-519
7. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica 2004;218:223-236
8. Jaanus S, Lesher G. Anti-inflammatory drugs. In: Bartlett JD, Jaanus SD, editors, Clinical ocular pharmacology. 3rd edition. Butterworth Heinemann, Boston, MA; 1995. p. 303-335
9. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33-55
10. Raizman M. Corticosteroid therapy of eye disease fifty years later. Arch Ophthalmol 1996;114:1000-1001
11. Whitcup SM, Ferris FL III. New corticosteroids for the treatment of ocular inflammation. Am J Ophthalmol 1999;127:597-599
12. Riordan-Eva P, Whitcher J. Vaughan & asbury's general ophthalmology. 17th edition. McGraw-Hill, Columbus, OH; 2008
13. Friedlaender MH, Howes J, Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Am J Ophthalmol 1997;123:455-464
14. Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 1997;23:31-36
15. Dell SJ, Shulman DG, Lowry GM, Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol 1997;123:791-797
16. Joss JD, Craig TJ. Seasonal allergic conjunctivitis: overview and treatment update. J Am Osteopath Assoc 1999;99:S13-18
17. El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2001;12:4-8
18. Rowen S. Preoperative and postoperative medications used for cataract surgery. Curr Opin Ophthalmol 1999;10:29-35
19. Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 1999;127:537-544
20. McCluskey PJ, Towler HM, Lightman S. Management of chronic uveitis. BMJ 2000;320:555-558
21. Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999;15:439-450
22. Thadani SM, Foster CS. Treatment of ocular inflammation in children. Paediatr Drugs 2004;6:289-301
23. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-491
24. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965;4:198-205
25. Burde R, Becker B. Corticosteroid-induced glaucoma and cataracts in contact lens wearers. JAMA 1970;213:2075-2077
26. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 2000;20:58-101
27. Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J 2005;7:E820-33
28. Druzgala P, Hochhaus G, Bodor N. Soft drugs-10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol 1991;38:149-154
29. Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991;10:933-937
30. Bodor N, Bodor N, Wu WM. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Curr Eye Res 1992;11:525-530
31. Samudre S, Lattanzio F, Loose-Thurman P, Sheppard J. Comparison of topical steroids for uveitis. Invest Ophthalmol Vis Sci 2002;43:E-abstract 4284
32. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmology 1998;105:1780-1786
33. Stewart R, Horwitz B, Howes J, et al. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. J Cataract Refract Surg 1998;24:1480-1489
34. Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993;9:157-165
35. Holland EJ, Bartlett JD, Paterno MR, et al. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008;27:50-55
36. Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 1998;7:266-269
37. Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993;12:313-321
38. Dell SJ, Lowry GM, Northcutt JA, et al. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 1998;102:251-255
39. Ilyas H, Slonim CB, Braswell GR, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 2004;30:10-13
40. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 1999;106:362-369
41. Manabe S, Bucala R, Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest 1984;74:1803-1810
42. FDA post marketing adverse events reports. Available from: http://www.fda.gov/Drugs/GuidanceCompliance RegulatoryInformation/Surveillance/ AdverseDrugEffects/default.htm [Last accessed 27 January 2010]
43. Holland E, Djalilian A, Sanderson J. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea 2009;28:1139-1143
44. Cagle G, Davis S, Rosenthal A, Smith J. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res 1981-1982;1:523-534
45. Dajcs J, Moreau J, Stroman D, et al. The effectiveness of tobramycin and ocuflox in a prophylaxis model of Staphylococcus keratitis. Curr Eye Res 2001;23:60-63
46. Engel L, Callegan M, Hobden J, et al. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res 1995;14:229-234
47. Zylet® [package insert]. Tampa FL: Bausch & Lomb Inc.; 2004
48. Zylet. United States Prescribing Information. 2005. Available from: http://www.drugs.com/ pdr/Zylet-Ophthalmic-Suspension.html. [Last accessed 25 Jan 2010]
49. Data on file, Bausch & Lomb Incorporated, Rochester, NY; 2004
50. Hammersmith KM, Cohen EJ, Blake TD, et al. Blepharokeratoconjunctivitis in children. Arch Ophthalmol 2005;123:1667-1670
51. Rhee SS, Mah FS. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo- keratoconjunctivitis. Adv Ther 2007;24:60-67
52. TobraDex [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2009
53. White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5%/ tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin 2008;24:287-296
54. Bartlett JD, Holland EJ, Usner DW, et al. Tolerability of loteprednol/tobramycin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group study. Curr Med Res Opin 2008;24:2219-2227
55. American Academy of Allergy Asthma and Immunology (AAAAI). The allergy report. Volume 3. Conditions that may have an allergic component. AAAAI, Milwaukee, WI; 2000
56. American Academy of Ophthalmology. Summary benchmarks for the AAO Preferred Practice Pattern® (PPP) guidelines. American Academy of Ophthalmology, San Francisco; 2008. p. 1-22. Available from: http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmarks.aspx [Last accessed 24 September 2009]
57. Bartlett JD, Woolley TW, Adams CM. Identification of high intraocular pressure responders to topical ophthalmic corticosteroids. J Ocul Pharmacol 1993;9:35-45